Genomic Determinants of Immune Variation: Epidemiologic Perspectives on Mechanisms and Clinical Translation
DOI:
https://doi.org/10.64784/067Keywords:
immunogenomics, genomic variation, somatic mutations, epigenomics, single-cell profiling, immune heterogeneity, precision medicine, immunotherapy, CRISPR, CAR-T, tumor mutational burden, HLA variation, Latin American , populationsAbstract
Advances in genomics and immunology have redefined the understanding of immune regulation, disease susceptibility and therapeutic response. This review synthesizes evidence across multiple biological scales—including germline variation, somatic mutations, epigenomic architecture and single-cell immune heterogeneity—to elucidate how genomic mechanisms shape immune function in health and disease. Emphasis is placed on the translational relevance of these mechanisms, particularly in the context of cancer immunotherapy, autoimmune risk stratification and emerging engineered-immunity platforms such as CRISPR-based editing and CAR T-cell therapies. The analysis also highlights the persistent underrepresentation of populations from Mexico, Colombia and Ecuador in genomic datasets, underscoring the need for inclusive precision-medicine strategies. By integrating mechanistic, technological and clinical dimensions, this review outlines the conceptual foundations of immunogenomics and identifies the opportunities and challenges that will shape its evolution as a global, population-relevant discipline.
References
[1] L. A. O’Neill, D. G. Golenbock, and A. G. Bowie, “The history of Toll-like receptors—redefining innate immunity,” Nature Reviews Immunology, vol. 13, no. 6, pp. 453–460, 2013, doi: 10.1038/nri3446.
[2] D. C. Koboldt et al., “The next-generation sequencing revolution and its impact on genomics,” Nature Reviews Genetics, vol. 13, no. 1, pp. 1–16, 2013, doi: 10.1038/nrg3241.
[3] D. M. Fowler and S. Fields, “Deep mutational scanning: a new style of protein science,” Nature Methods, vol. 11, no. 8, pp. 801–807, 2014, doi: 10.1038/nmeth.3027.
[4] L. M. M. Ng and D. MacArthur, “Human genetic variation and its impact on immune disease,” Nature Reviews Genetics, vol. 23, no. 1, pp. 1–17, 2022, doi: 10.1038/s41576-021-00421-1.
[5] J. C. Marquez-Lago and J. R. Torres, “Systems immunology: complexity captured by holistic approaches,” Frontiers in Immunology, vol. 8, p. 1670, 2017, doi: 10.3389/fimmu.2017.01670.
[6] A. S. Shalek and M. Benson, “Single-cell genomics and immune dynamics,” Annual Review of Immunology, vol. 39, pp. 583–609, 2021, doi: 10.1146/annurev-immunol-101819-074850.
[7] P. Zhang et al., “CRISPR–Cas systems and genome editing: molecular mechanisms and clinical applications,” Cell, vol. 184, no. 1, pp. 14–35, 2021, doi: 10.1016/j.cell.2020.12.020.
[8] E. Shapiro, T. Biezuner, and S. Linnarsson, “Single-cell sequencing-based technologies,” Nature Reviews Genetics, vol. 14, no. 9, pp. 618–630, 2013, doi: 10.1038/nrg3542.
[9] I. Tirosh et al., “Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq,” Science, vol. 352, no. 6282, pp. 189–196, 2016, doi: 10.1126/science.aad0501.
[10] J. D. Buenrostro et al., “ATAC-seq: A method for assaying chromatin accessibility genome-wide,” Nature Methods, vol. 10, no. 12, pp. 1213–1218, 2013, doi: 10.1038/nmeth.2688.
[11] J. E. Lavoie et al., “Genetic architecture of autoimmune diseases,” Nature Reviews Immunology, vol. 21, no. 5, pp. 302–317, 2021, doi: 10.1038/s41577-021-00523-3.
[12] C. A. MacKay et al., “HLA variation and disease susceptibility,” Nature Reviews Genetics, vol. 23, no. 2, pp. 110–127, 2022, doi: 10.1038/s41576-021-00449-3.
[13] P. Brodin and V. Jojic, “Human immune system variation,” Nature Reviews Immunology, vol. 16, no. 3, pp. 167–178, 2016, doi: 10.1038/nri.2015.19.
[14] B. J. Schaub and C. L. Boyce, “Gene–environment interactions and the origins of allergic disease,” Science, vol. 345, no. 6191, pp. 275–279, 2014, doi: 10.1126/science.1243707.
[15] D. A. H. Jones et al., “Somatic mutations in immune cells and their role in disease,” Nature Genetics, vol. 54, no. 2, pp. 120–130, 2022, doi: 10.1038/s41588-021-01007-8.
[16] C. Robert, “A decade of immune-checkpoint inhibitors in cancer therapy,” Nature Communications, vol. 11, no. 1, p. 3801, 2020, doi: 10.1038/s41467-020-17670-y.
[17] J. D. Wolchok et al., “Nivolumab and ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013, doi: 10.1056/NEJMoa1302369.
[18] M. D. Hellmann et al., “Tumor mutational burden and immunotherapy response,” Cancer Cell, vol. 33, no. 5, pp. 843–861, 2018, doi: 10.1016/j.ccell.2018.04.007.
[19] W. Chen and M. J. Mellman, “Elements of cancer immunotherapy,” Nature, vol. 541, no. 7637, pp. 321–330, 2017, doi: 10.1038/nature21349.
[20] C. H. June et al., “CAR T cell immunotherapy for human cancer,” Science, vol. 359, no. 6382, pp. 1361–1365, 2018, doi: 10.1126/science.aar6711.
